Technical Analysis for VTGN - VistaGen Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 1.32 3.94% 0.05
VTGN closed up 3.94 percent on Monday, March 18, 2019, on 1.15 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical VTGN trend table...

Date Alert Name Type % Chg
Mar 18 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Mar 18 Wide Bands Range Expansion 0.00%
Mar 15 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 3.94%
Mar 15 New Uptrend Bullish 3.94%
Mar 15 Wide Bands Range Expansion 3.94%
Mar 14 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 3.13%
Mar 14 Crossed Above 20 DMA Bullish 3.13%
Mar 14 Inside Day Range Contraction 3.13%
Mar 14 Wide Bands Range Expansion 3.13%
Mar 13 20 DMA Resistance Bearish 4.76%

Older signals for VTGN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). The company's lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform, including drug rescue to develop proprietary new chemical entities (NCEs) for internal drug candidate pipeline; and regenerative medicine (RM) using blood, cartilage, heart, and liver cells derived from hPSC technology. The company is also involved in the development of CardioSafe 3D, an in vitro bioassay system for predicting potential cardiotoxicity of new chemical entities (NCEs), including drug rescue NCEs; and LiverSafe 3D, a bioassay system to predict potential liver toxicity of new drug candidates, including potential drug metabolism issues and adverse drug-drug interactions. It has strategic collaborations with University Health Network for hPSC technology research and development; Synterys, Inc. to design, produce, and analyze drug rescue NCEs; and Cato Research, Ltd. for regulatory expertise and clinical development support. The company also has cooperative research and development agreement with the U.S. National Institute of Mental Health for the Phase II clinical study of AV-101. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Health Biopharmaceutical Pharmaceutical Industry Diseases Drug Discovery Clinical Trial Disorders Health Sciences Regenerative Medicine Pharmaceutical Sciences Major Depressive Disorder Antidepressants Treatment Of Major Depressive Disorder Clinical Pharmacology Av Chemical Entities Drug Metabolism Nmda Receptor Antagonists
Is VTGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.44
52 Week Low 0.81
Average Volume 279,708
200-Day Moving Average 1.5386
50-Day Moving Average 1.4881
20-Day Moving Average 1.2405
10-Day Moving Average 1.222
Average True Range 0.0987
ADX 23.67
+DI 21.9929
-DI 19.7914
Chandelier Exit (Long, 3 ATRs ) 1.4539
Chandelier Exit (Short, 3 ATRs ) 1.3461
Upper Bollinger Band 1.4355
Lower Bollinger Band 1.0455
Percent B (%b) 0.7
BandWidth 31.438936
MACD Line -0.0665
MACD Signal Line -0.0931
MACD Histogram 0.0266
Fundamentals Value
Market Cap 12.38 Million
Num Shares 9.38 Million
EPS -1.35
Price-to-Earnings (P/E) Ratio -0.98
Price-to-Sales 7.65
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.46
Resistance 3 (R3) 1.46 1.42 1.43
Resistance 2 (R2) 1.42 1.39 1.42 1.42
Resistance 1 (R1) 1.37 1.36 1.35 1.37 1.42
Pivot Point 1.33 1.33 1.32 1.33 1.33
Support 1 (S1) 1.28 1.30 1.26 1.28 1.22
Support 2 (S2) 1.24 1.27 1.24 1.22
Support 3 (S3) 1.19 1.24 1.21
Support 4 (S4) 1.19